Pieris Pharma Appoints Chief Development Officer
This article was originally published in Scrip
Executive Summary
Pieris Pharmaceuticals, Inc., a biotechnology company advancing novel biotherapeutics through its Anticalin technology platform, has named Dr. Louis Matis senior vice-president and chief development officer. Prior to joining Pieris, Matis was, since June 2011, executive director of strategic evaluation at Alexion Pharmaceuticals. He also worked at Alexion from 1993 to 2000, during which time he advanced to the position of chief scientific officer and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris (eculizumab).
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.